• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hybrid revascularization vs coronary bypass for coronary artery disease: a systematic review and meta-analysis
CONCLUSIONS: Our analysis shows hybrid coronary revascularization is a feasible alternative to traditional coronary artery bypass grafting. Short-and long-term outcomes including mortality, MACE, and postoperative morbidity are similar between both groups, while hybrid approaches are associated with decreased perioperative morbidity.PMID:35343660 | DOI:10.23736/S0021-9509.22.12163-4
Source: The Journal of Cardiovascular Surgery - March 28, 2022 Category: Cardiovascular & Thoracic Surgery Authors: David E Hinojosa-Gonzalez Luis C Bueno-Gutierrez Marcelo Salan-Gomez Eduardo Tellez-Garcia Isabela Ramirez-Mulhern Diego Sepulveda-Gonzalez Diego Ramonfaur Andres Roblesgil-Medrano Eduardo Flores-Villalba Source Type: research

Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
CONCLUSION: Preoperative use of eptifibatide vs. placebo is linked to significantly reduced 12-month MACCE rate in patients with NSTE-ACS requiring urgent CABG, while it simultaneously seems not to confer a greater risk of postoperative bleeding. PMID: 26771733 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Surgery - January 16, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Wilczynski M, Wybraniec MT, Milewski K, Sanak M, Wita K, Buldak Ł, Kondys M, Buszman P, Bochenek A Tags: J Cardiovasc Surg (Torino) Source Type: research

Eptifibatide infusion versus placebo in high risk patients with non-st segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. a prospective multicenter randomized placebo-controlled clinical trial.
CONCLUSION: Preoperative use of eptifibatide vs. placebo is linked to significantly reduced 12--month MACCE rate in patients with NSTE--ACS requiring urgent CABG, while it simultaneously seems not to confer a greater risk of postoperative bleeding. PMID: 25394877 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Surgery - November 14, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Wilczynski M, Wybraniec MT, Milewski K, Sanak M, Wita K, Buldak L, Kondys M, Buszman P, Bochenek A Tags: J Cardiovasc Surg (Torino) Source Type: research